leadf
logo-loader
viewTiziana Life Sciences PLC
(
NASDAQ:TLSALSE:TILSFRA:RTRAOTC:TIZAF
)

Tiziana Life hails 'major accomplishment as nasally administered antibody shows potential to treat degenerative diseases such as MS

The latest data come from a phase I assessment of Foralumab, which is being developed for a range of diseases

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered nasally.

The latest data come from a phase I assessment of Foralumab, which is being developed for a range of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease.

Its delivery via the nose rather than orally or by injection is being pioneered by Tiziana and Dr Howard Weiner, chair of the company’s scientific board and a Harvard professor.

The study revealed the treatment was well-tolerated at all doses and there were no apparent symptoms of severe toxicity.

Importantly, the drug showed “significant positive effects” at a 50 micrograms per day dose on T-cell subsets and inflammatory biomarkers.

Tiziana said the latest data supported clinical and pre-clinical studies showing that this route of administration (where the medication is inhaled via the nose) is capable of inducing “site-targeted immunomodulation and anti-inflammatory effects”.

Specifically, it chimed with the feedback received from a recent evaluation of Foralumab in COVID sufferers across a range of doses

The company said the biochemical and physiological (pharmacodynamic) results “point to a clinical dose range that Tiziana intends to test in further clinical development among MS patients”.

“This study demonstrates for the first time that nasally administered Foralumab, at the identified optimal dose of 50 mcg/day, induces immunomodulatory effects capable of providing clinical benefit to treated subjects,” said Weiner.

He described the results of the phase I trial as a “major accomplishment” that provided the scientific rationale to move forward with the further clinical development of nasally administered Foralumab in patients with neurodegenerative diseases.

Quick facts: Tiziana Life Sciences PLC

Follow
NASDAQ:TLSA

Price: 1.51 USD

Market Cap: $146.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: A different approach, tackling disease using a safe,...

Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come.  The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal...

2 days, 13 hours ago

2 min read